← Back to Search

Procedure

rTMS for Methamphetamine Addiction

N/A
Recruiting
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 months
Awards & highlights

Summary

This trial is investigating if high-frequency repetitive transmagnetic stimulation (HF-rTMS) can help to reduce cue-induced craving for methamphetamine in adults with methamphetamine use disorder (MUD). The participants will be randomly assigned to receive either real or sham rTMS, and will be shown either methamphetamine or neutral cues before each session.

Who is the study for?
This trial is for adults with methamphetamine use disorder who have used at least 0.5 g per day, five days a week, for over a year and are currently detoxed with a desire to quit. They must not have other drug abuses (except nicotine), serious mental health issues, neurological disorders, cardiovascular diseases or metal implants in the head/chest.
What is being tested?
The study tests if high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) can reduce craving in meth users when directed at the brain's left frontal region. Participants will be randomly assigned to receive real or sham rTMS while being shown drug-related or neutral images over several weeks.
What are the potential side effects?
rTMS may cause discomfort at the stimulation site, headache, lightheadedness, or seizures in rare cases. Sham rTMS has no active side effects but may include similar sensations due to placebo effect.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Effect of rTMS directed at left DLPFC on craving for methamphetamine as assessed by a Visual Analog Scale (VAS).
Effect of rTMS directed at left DLPFC on craving for methamphetamine as assessed by the Severity of Dependence Scale.
Effect of rTMS directed at left DLPFC on craving for methamphetamine as assessed by the Stimulant Craving Questionnaire (STCQ).
Secondary study objectives
Methamphetamine
Methamphetamine

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Treatment rTMS + meth picturesExperimental Treatment2 Interventions
Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving real rTMS treatments. This group will be referred to as real METH (RM).
Group II: Treatment rTMS + neutral picturesActive Control2 Interventions
Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving real rTMS treatments. This group will be referred to as real neutral (RN).
Group III: Sham rTMS + meth picturesPlacebo Group2 Interventions
Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving sham rTMS treatments. This group will be referred to as sham METH (SM).
Group IV: Sham rTMS + neutral picturesPlacebo Group2 Interventions
Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving sham rTMS treatments. This group will be referred to as sham neutral (SN).

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
994 Previous Clinical Trials
7,386,898 Total Patients Enrolled
~6 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top